A phase III, double-blind, comparative study of NE-58095 (once-monthly formulation)
Latest Information Update: 27 May 2016
At a glance
- Drugs Risedronic acid (Primary)
- Indications Osteoporosis; Postmenopausal osteoporosis
- Focus Registrational; Therapeutic Use
- Sponsors Ajinomoto Pharma; Takeda
- 27 May 2016 New trial record